Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 7/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.68 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.60 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | DAO | P14920 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30189510 | 1.00 | FLT3 (0.68) | FLT3PDGFRBPDGFRAKMT2AMEN1 | |
| SCHEMBL20494459 | 0.88 | FLT3 (0.55) | FLT3PDGFRBPDGFRAKMT2AMEN1 | |
| SCHEMBL30071213 | 0.88 | FLT3 (0.55) | FLT3PDGFRBPDGFRAKMT2AMEN1 | |
| SCHEMBL24113306 | 0.87 | FLT3 (0.68) | FLT3PDGFRBPDGFRAKMT2AMEN1 | |
| SCHEMBL335235 | 0.87 | PDGFRB (0.79) | FLT3PDGFRBPDGFRAKMT2AMEN1 | |
| SCHEMBL29368200 | 0.85 | FLT3 (0.67) | FLT3PDGFRBPDGFRAKMT2AMEN1 | |
| SCHEMBL3883246 | 0.85 | FLT3 (0.67) | FLT3PDGFRBPDGFRAKMT2AMEN1 | |
| SCHEMBL216170 | 0.85 | FLT3 (0.67) | FLT3PDGFRBPDGFRAKMT2AMEN1 | |
| SCHEMBL9371227 | 0.84 | KDM4E (0.59) | FLT3PDGFRBPDGFRAKMT2AMEN1 | |
| SCHEMBL3641124 | 0.84 | EIF4A3 (0.63) | FLT3PDGFRBPDGFRAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109212052-B | Gas chromatography-mass spectrometry combined method for measuring five trace indole carboxylic acid compounds in water source water | 丁立平 | 2021-05-11 | — | — | CN | claimed |
| CN-109212052-A | The gas chromatography-mass spectrometry of five kinds of trace indol-carbocylic acids compounds in a kind of measurement source water | 丁立平 | 2019-01-15 | — | — | CN | claimed |
| EP-2069289-B1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS | SANOFI SA (FR) | 2013-10-02 | — | — | EP | claimed |
| EP-2167077-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | claimed |
| EP-2149551-A1 | N-(indol-3-ylalkyl)-(hetero)arylamid derivatives as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2010-02-03 | — | — | EP | claimed |
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | claimed |
| CN-101516834-A | Isoserine derivatives for use as coagulation factor ixa inhibitors | SANOFI AVENTIS (FR) | 2009-08-26 | — | — | CN | claimed |
| WO-2009063495-A2 | SUBSTITUTED INDOLE AND ITS DERIVATIVES AS CANNABINOID MODULATORS | CADILA HEALTHCARE LIMITED (IN) | 2009-05-22 | — | — | WO | claimed |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | claimed |
| WO-2008152099-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | claimed |
| US-6869953-B2 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2005-03-22 | — | — | US | claimed |
| US-20040192744-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HAAG RAINER (DE) | 2004-09-30 | — | — | US | claimed |
| US-20030139404-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2003-07-24 | — | — | US | claimed |
| EP-4660193-A1 | INDOLE COMPOUND DECOMPOSING IKZF2, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2025-12-10 | — | — | EP | disclosed |
| US-20250302842-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS | Jubilant Epipad LLC | 2025-10-02 | — | — | US | disclosed |
| EP-4601635-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| WO-1996018628-A1 | ALKYL SUBSTITUTED PIPERADINYL AND PIPERAZINYL ANTI-AIDS COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1996-06-20 | — | — | WO | disclosed |
| US-5489593-A | Anti-aids piperazines | THE UPJOHN COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| EP-0507861-A1 | DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS. | UPJOHN CO (US) | 1992-10-14 | — | — | EP | disclosed |
| WO-1991009849-A1 | DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS | THE UPJOHN COMPANY (US) | 1991-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302842-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS | NES, VHL, ETV6 | FLT3 13/4885PDGFRB 230/4885PDGFRA 40/4885 |
| US-20040192744-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | NAT1, CYP1A1, UGT1A1 | FLT3 1006/4885PDGFRB 3137/4885PDGFRA 2183/4885 |
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | TFPI, F2, F9 | FLT3 1315/4885PDGFRB 2390/4885PDGFRA 2018/4885 |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | FLT3 2000/4885PDGFRB 296/4885PDGFRA 210/4885 |
| US-20030139404-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | NAT1, CYP1A1, UGT1A1 | FLT3 1006/4885PDGFRB 3137/4885PDGFRA 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.